Last reviewed · How we verify

Persantin

Boehringer Ingelheim · Phase 1 active Small molecule Under review

Persantin is a Small molecule drug developed by Boehringer Ingelheim. It is currently in Phase 1 development for Atrial fibrillation, Chronic heart failure, Myocardial Perfusion Imaging Adjunct.

Persantine, also known as Dipyridamole, is a small molecule inhibitor of the equilibrative nucleoside transporter 1. It is used to prevent blood clot formation and has been studied in various conditions, including kidney transplantation, cerebrovascular accidents, and hypertension.

Likelihood of approval
10.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Cardiovascular Phase 3 risk -2.0pp
    Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
  • Big-pharma sponsor +3.0pp
    Boehringer Ingelheim is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036 —
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePersantin
SponsorBoehringer Ingelheim
TargetEquilibrative nucleoside transporter 4, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 1

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Persantin

What is Persantin?

Persantin is a Small molecule drug developed by Boehringer Ingelheim, indicated for Atrial fibrillation, Chronic heart failure, Myocardial Perfusion Imaging Adjunct.

What is Persantin used for?

Persantin is indicated for Atrial fibrillation, Chronic heart failure, Myocardial Perfusion Imaging Adjunct, Platelet Aggregation Inhibition, Prevention of Cerebral Thrombosis.

Who makes Persantin?

Persantin is developed by Boehringer Ingelheim (see full Boehringer Ingelheim pipeline at /company/boehringer-ingelheim).

What development phase is Persantin in?

Persantin is in Phase 1.

What does Persantin target?

Persantin targets Equilibrative nucleoside transporter 4, Sodium/nucleoside cotransporter 1, ATP-binding cassette sub-family G member 2.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing